Cooley M&A

JANUARY 22, 2021

General Trends in Life Sciences M&A. In contrast, aggregate M&A deal value for the life sciences sector was down nearly 50% when compared to 2019, with the first half of 2020 particularly dismal in the wake of market uncertainty caused by the pandemic.

M&A 40

M&A Mergers and Acquisitions Collaboration Mergers 40

How2Exit

OCTOBER 2, 2023

Their team is experienced in M&A, and they hire the best talent available. rn About The Guest(s): Corey Veverka is the owner of TBS, a company that specializes in validation and compliance for pharmaceutical manufacturing facilities. Reconciled sets the standard for consistency and quality that you can count on.

Business 130

Business Finance Finance Recruitment 130

Wizenius

JUNE 28, 2023

Macroeconomic Factors: The global economic landscape can significantly impact growth rates. Pharmaceutical Sector: In the pharmaceutical industry, growth rates can be influenced by factors like patent expirations, drug pipelines, and regulatory approvals.

DCF 52

DCF Financial Modeling Financial Models Discounted Cash Flow 52

Peak Frameworks

SEPTEMBER 19, 2023

Proponents argue that by fulfilling this responsibility, firms indirectly benefit society by driving economic growth and innovation. The distinction between them is crucial for understanding a company's obligations, its strategy, and the interplay of interests within its ecosystem. What is a Shareholder?

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

Cooley M&A

JANUARY 20, 2022

General trends in life sciences M&A. While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. driven assets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

OCTOBER 24, 2024

While this mantra may help bruised egos on the playground, it’s of no use in M&A disputes. Alexion Pharmaceuticals (Del. In both Fortis v. Johnson & Johnson (Del. September 2024) and SRS v. July 2024), buyer-friendly covenants enabled the buyer to prevail in an earnout dispute. billion up front in cash and up to $2.35

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Negotiation Sale 52

Cooley M&A

JULY 10, 2017

Similarly, sellers (particularly financial investors) in private M&A transactions are increasingly seeking the right to be able to monetize their rights to contingent consideration by requesting royalty-like earn-out streams and requesting a right to sell the potential future payments to a single third-party purchaser. Private placement.

Securities 52

Securities IT Investors M&A 52

Cooley M&A

OCTOBER 29, 2018

M&A practitioners have long advised boards of directors that the Delaware courts have never found that the events or circumstances in a particular transaction met the contractual standard of having a material adverse effect (or MAE) as defined in a merger or acquisition agreement. We can no longer give this advice. 2018-0300-JTL (Del.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Business Pharmaceutical 52

InvestmentBank.com

AUGUST 14, 2019

The benefits of VR are not limited to language immersion, architecture, interior design, space expedition, biology, chemistry or pharmaceutical practices. Students (K-12) participating in schools with technological integration efforts achieved an increase of 94 points on average in SAT I performance [1]. billion in 2018 in the U.S.,

Education 52

Education Mergers and Acquisitions Capital Investment 52

Software Equity Group

AUGUST 20, 2024

The software landscape is dynamic, and strategic buyers are continuously seeking new and innovative ways to gain a competitive edge. One strategy gaining momentum is the acquisition of high-growth SaaS companies. This trend goes beyond simply acquiring market share; it creates a win-win scenario for both parties.

Investment 52

Investment Management Acquisitions Business 52

MergersCorp M&A International

NOVEMBER 16, 2024

The election of Donald Trump as President of the United States in November 2024 marked a significant change in the political and economic landscape of the country. His presidency brought with it a unique set of policies and attitudes that would directly influence the realm of mergers and acquisitions (M&A).

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Acquisitions M&A 52

Cooley M&A

JANUARY 21, 2022

One year into his administration, President Joe Biden has made clear that aggressive competition policy is on the agenda. With a team of progressives filling leadership roles at the Federal Trade Commission and in the Antitrust Division of the US Department of Justice, companies are able to predict what the next several years may look like.

Mergers and Acquisitions 40

Mergers and Acquisitions Mergers Pharmaceutical IT 40

Cooley M&A

JANUARY 18, 2017

If she is named chair, Ohlhausen can in turn immediately name new directors to head the Bureaus of Competition, Consumer Protection and Economics. Transition to a Trump Administration is top of the agenda. Trump has the ability, as early as Inauguration Day, to name Maureen Ohlhausen as either acting chair or chair of the Commission.

Mergers and Acquisitions 52

Mergers and Acquisitions Pharmaceutical Mergers Investment 52

InvestmentBank.com

MAY 18, 2021

The healthcare sector in the United States is a large driver of economic output. The healthcare industry is formed of numerous subsectors including pharmaceutical services, diagnostics, medical technologies, and managed healthcare. Payor services and pharmaceutical services have generated the most return throughout 2016 and in 1Q 2017.

Healthcare 40

Healthcare M&A Valuation Hospitality 40